#United States #Salt Lake City #Lipocine #LPCN 1154 #postpartum depression

Lipocine Doses First Participant in BLOOM Phase 3 Study for LPCN 1154

On November 10, 2026, Lipocine Inc. announced a significant milestone in its clinical development program for LPCN 1154, an oral formulation designed to treat postpartum depression (PPD). The company successfully dosed its first participant in the BLOOM study, a Phase 3 trial evaluating the efficacy and safety of LPCN 1154. This therapeutic option is aimed at providing rapid symptom relief within a 48-hour course of treatment, to be taken at home.

Background on LPCN 1154

LPCN 1154 is an investigational medication that functions as an oral brexanolone. Brexanolone is a naturally occurring neuroactive steroid known to interact with GABA-A receptors. Unlike traditional treatments requiring hospital visits, LPCN 1154 aims to offer a more accessible solution for new mothers struggling with PPD. The ongoing study targets approximately 120 participants and seeks to refine the data quality and representation of this patient population, drawing on insights gained from previous trials.

Design of the BLOOM Study

The BLOOM study is carefully constructed to include learnings from Lipocine's earlier Phase 3 trials, reflecting feedback from the FDA. The study is placebo-controlled and will evaluate the change in depression levels as measured by the Hamilton Depression Rating Scale (HAM-D17) 60 hours after initial dosing. The trial aims to support a potential New Drug Application (NDA) submission through the 505(b)(2) pathway, which allows for a streamlined review process when sufficient clinical evidence exists from prior studies.

Dr. Mahesh Patel, President and CEO of Lipocine, stated, "Our objective is to offer a treatment option that addresses the urgent needs of postpartum women. We are committed to ensuring that the BLOOM study's design will enhance participant enrollments reflective of real-world PPD cases and yield reliable data outcomes."

Enhancements in Study Design

To improve the quality of results, the BLOOM study has implemented several operational enhancements:

• - Selection Criteria for Sites: The trial incorporates rigorous third-party support for site selection, ensuring geographic diversity and participation from reputable academic centers. Each site is limited in the number of participants to optimize data integrity.
• - Minimized Placebo Response: Adjustments have been made to reduce potential placebo effects by streamlining participant contact with staff and employing centralized evaluations for screening.
• - Analytical Measures: Planned sensitivity analyses will track outlier sites and pharmacokinetic data, contributing to a robust understanding of the data gathered throughout the study.

These design improvements are not guaranteed to establish efficacy or assure successful outcomes but are steps toward enhancing the study's reliability.

The Need for Effective Treatments

Postpartum depression affects many women during the critical period following childbirth, often impairing their daily functioning and the bonding process with their infants. Symptoms such as persistent sadness, anxiety, and feelings of inadequacy underscore the urgent need for timely, effective interventions.

Current treatment options can be limited and come with various side effects, highlighting the significance of developing new therapies like LPCN 1154. The lack of established treatments that can meet the practical needs and lifestyle challenges of new mothers make this development crucial.

Lipocine is committed to advancing LPCN 1154 while ensuring patient safety and efficacy are paramount during this investigational process. The company envisions bringing a well-tolerated and effective solution to postpartum depression into the market soon.

For more information about Lipocine and its ongoing studies, please visit lipocine.com.